Literature DB >> 11423552

The transcription factors SOX9 and SOX10 are vitiligo autoantigens in autoimmune polyendocrine syndrome type I.

H Hedstrand1, O Ekwall, M J Olsson, E Landgren, E H Kemp, A P Weetman, J Perheentupa, E Husebye, J Gustafsson, C Betterle, O Kämpe, F Rorsman.   

Abstract

Vitiligo is common in the hereditary disorder autoimmune polyendocrine syndrome type I (APS I). Patients with APS I are known to have high titer autoantibodies directed against various tissue-specific antigens. Using sera from APS I patients for immunoscreening of a cDNA library from human scalp, we identified the transcription factors SOX9 and SOX10 as novel autoantigens related to this syndrome. Immunoreactivity against SOX9 was found in 14 (15%) and against SOX10 in 20 (22%) of the 91 APS I sera studied. All patients reacting with SOX9 displayed reactivity against SOX10, suggesting shared epitopes. Among the 19 patients with vitiligo, 12 (63%) were positive for SOX10 (p < 0.0001). Furthermore, three of 93 sera from patients with vitiligo unrelated to APS I showed strong reactivity against SOX10, which may indicate a more general role of SOX10 as an autoantigen in vitiligo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11423552     DOI: 10.1074/jbc.M102391200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

1.  The Waardenburg syndrome type 4 gene, SOX10, is a novel tumor-associated antigen identified in a patient with a dramatic response to immunotherapy.

Authors:  Hung T Khong; Steven A Rosenberg
Journal:  Cancer Res       Date:  2002-06-01       Impact factor: 12.701

Review 2.  Sox proteins in melanocyte development and melanoma.

Authors:  Melissa L Harris; Laura L Baxter; Stacie K Loftus; William J Pavan
Journal:  Pigment Cell Melanoma Res       Date:  2010-04-22       Impact factor: 4.693

3.  Patients affected by vitiligo and autoimmune diseases do not show antibodies interfering with the activity of the melanocortin 1 receptor.

Authors:  P Agretti; G De Marco; D Sansone; C Betterle; G Coco; A Dimida; E Ferrarini; A Pinchera; P Vitti; M Tonacchera
Journal:  J Endocrinol Invest       Date:  2010-03-22       Impact factor: 4.256

4.  SOX9 is a key player in ultraviolet B-induced melanocyte differentiation and pigmentation.

Authors:  Thierry Passeron; Julio C Valencia; Corine Bertolotto; Toshihiko Hoashi; Elodie Le Pape; Kaoruko Takahashi; Robert Ballotti; Vincent J Hearing
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-16       Impact factor: 11.205

Review 5.  Lessons from primary immunodeficiencies: Autoimmune regulator and autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.

Authors:  Gregory M Constantine; Michail S Lionakis
Journal:  Immunol Rev       Date:  2019-01       Impact factor: 12.988

Review 6.  Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy.

Authors:  Kai Kisand; Pärt Peterson
Journal:  J Clin Immunol       Date:  2015-07-05       Impact factor: 8.317

Review 7.  SOXopathies: Growing Family of Developmental Disorders Due to SOX Mutations.

Authors:  Marco Angelozzi; Véronique Lefebvre
Journal:  Trends Genet       Date:  2019-07-06       Impact factor: 11.639

8.  Activating autoantibodies against the calcium-sensing receptor detected in two patients with autoimmune polyendocrine syndrome type 1.

Authors:  E Helen Kemp; Nikos G Gavalas; Kai J E Krohn; Edward M Brown; Philip F Watson; Anthony P Weetman
Journal:  J Clin Endocrinol Metab       Date:  2009-10-16       Impact factor: 5.958

Review 9.  Autoimmune polyglandular syndrome Type 2: the tip of an iceberg?

Authors:  C Betterle; F Lazzarotto; F Presotto
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

Review 10.  Immune deficiency disorders with autoimmunity and abnormalities in immune regulation-monogenic autoimmune diseases.

Authors:  Heather K Lehman; Mark Ballow
Journal:  Clin Rev Allergy Immunol       Date:  2008-04       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.